These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 19318598

  • 41. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
    Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H, MOVER Study Group.
    Calcif Tissue Int; 2013 Aug; 93(2):137-46. PubMed ID: 23644930
    [Abstract] [Full Text] [Related]

  • 42. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study.
    Eisman JA, Rizzoli R, Roman-Ivorra J, Lipschitz S, Verbruggen N, Gaines KA, Melton ME.
    Curr Med Res Opin; 2004 May; 20(5):699-705. PubMed ID: 15140336
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
    Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SM, Sebba A, Kagan R, Chen E, Thompson DE, de Papp AE.
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2631-7. PubMed ID: 16636120
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Tolerability of risedronate in postmenopausal women intolerant of alendronate.
    Adachi JD, Adami S, Miller PD, Olszynski WP, Kendler DL, Silverman SL, Licata AA, Li Z, Gomez-Panzani E.
    Aging (Milano); 2001 Oct; 13(5):347-54. PubMed ID: 11820707
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
    Siris ES, Modi A, Tang J, Gandhi S, Sen S.
    Curr Med Res Opin; 2014 Jan; 30(1):123-30. PubMed ID: 24102262
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series.
    López-Cedrún JL, Sanromán JF, García A, Peñarrocha M, Feijoo JF, Limeres J, Diz P.
    Br J Oral Maxillofac Surg; 2013 Dec; 51(8):874-9. PubMed ID: 23866309
    [Abstract] [Full Text] [Related]

  • 53. Oral Treatment With Bisphosphonates of Osteoporosis Does Not Increase the Risk of Severe Gastrointestinal Side Effects: A Meta-Analysis of Randomized Controlled Trials.
    Dömötör ZR, Vörhendi N, Hanák L, Hegyi P, Kiss S, Csiki E, Szakó L, Párniczky A, Erőss B.
    Front Endocrinol (Lausanne); 2020 Dec; 11():573976. PubMed ID: 33240217
    [Abstract] [Full Text] [Related]

  • 54. Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients.
    Sánchez-Escuredo A, Fuster D, Rubello D, Muxí A, Ramos A, Campos F, Marzola MC, Cook GJ, Tapias A, Torregrosa JV.
    Nucl Med Commun; 2015 Aug; 36(8):815-8. PubMed ID: 25856225
    [Abstract] [Full Text] [Related]

  • 55. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
    Thomson AB, Marshall JK, Hunt RH, Provenza JM, Lanza FL, Royer MG, Li Z, Blank MA, Risedronate Endoscopy Study Group.
    J Rheumatol; 2002 Sep; 29(9):1965-74. PubMed ID: 12233894
    [Abstract] [Full Text] [Related]

  • 56. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD, Faraawi RY, O'Mahony MF, Nayar A, Massaad R, Evans JK, Yacik C.
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG, Brown JP, Beary JF, Matzkin E, Darbie LM, Burgio DE, Racewicz AJ.
    Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
    [Abstract] [Full Text] [Related]

  • 59. Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women.
    Yu J, Goldshtein I, Shalev V, Chodick G, Ish-Shalom S, Sharon O, Modi A.
    Int J Clin Pract; 2015 Sep; 69(9):1007-14. PubMed ID: 26278464
    [Abstract] [Full Text] [Related]

  • 60. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P.
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.